Key challenges include structural modifications, peptide instability, incomplete digestion, complex fragmentation patterns, and detection of subtle PTMs
The Food and Drug Administration (FDA) has, for example, approved Ozempic for the treatment of diabetes and to lower the risk of cardiovascular problems
2003;14:S227S232
and limiting high-fiber foods initially can minimize nausea and digestive discomfort
By targeting these pathways, Retatrutide reduces hunger, promotes feelings of fullness, and helps the body burn fat more efficiently
Beyond their effects on blood sugar and weight management, GLP-1 receptor agonists may also lower cardiovascular risk, an advantage that sets them apart from many older diabetes treatments